A name that investors may remember as Ami Organics is now taking a much broader position in specialty chemicals. After changing its name to Acutaas Chemicals, the company is building businesses across pharmaceutical intermediates, battery chemicals and semiconductor materials.

The stock closed at around ₹3,281.60 on August 28, 2026, after touching an intraday high of ₹3,384 and a low of ₹3,235. The 52-week range was approximately ₹1,290.05 to ₹3,740.

For anyone researching the Acutaas Chemicals share price, the latest numbers present an interesting combination: very strong year-on-year growth, exceptionally high margins and significant expansion plans, but also a meaningful sequential decline in earnings.

From Ami Organics to Acutaas Chemicals

Acutaas Chemicals Limited was formerly known as Ami Organics Limited.

The company operates in specialty chemicals, with a strong base in advanced pharmaceutical intermediates. Its strategy is now expanding toward three major growth areas: pharmaceutical CDMO, battery chemicals and semiconductor materials.

This transformation is important because it gives the company exposure to multiple industries rather than relying exclusively on pharmaceutical intermediates.

The new businesses, however, also require substantial investment and successful execution.

Why Is Acutaas Chemicals Share Price in Focus?

The stock has delivered a significant rise over the past year.

At ₹3,281.60 on August 28, the share price was more than double its 52-week low of approximately ₹1,290.05.

The rally has been supported by strong financial performance and expectations around the company's new growth businesses.

Recent FY26 results were particularly impressive. Consolidated revenue from operations increased 33% to ₹1,339.4 crore, while profit after tax jumped 122.2% to ₹356.4 crore.

EBITDA more than doubled to ₹480.4 crore, and EBITDA margin expanded to 35.9% from 23% in FY25.

Q1 FY27 Results Show Another Strong Year-on-Year Jump

The June 2026 quarter continued the company's growth momentum.

Consolidated total revenue reached approximately ₹329.67 crore, representing year-on-year growth of 59.08%. Operating profit increased 122.10% to approximately ₹113.07 crore, while net profit reached ₹74.99 crore, up 70.4% from the year-ago quarter.

The operating margin was approximately 31.32% according to quarterly financial data.

These are strong numbers for a specialty-chemical company.

However, the quarter also highlights an important point that investors should not overlook.

Sequential Profit Declined Sharply

Compared with Q4 FY26, Q1 FY27 was significantly weaker.

Revenue declined approximately 23.8% sequentially, from ₹432.75 crore to ₹329.67 crore. Net profit fell about 44.2%, from ₹134.28 crore to ₹74.99 crore.

Operating profit also declined approximately 38.4% quarter over quarter.

This does not automatically indicate a deteriorating business.

Specialty-chemical sales can vary from quarter to quarter because of product mix, customer schedules, capacity utilisation and shipment timing.

Still, investors should monitor subsequent quarters to determine whether the company can sustain its high margins while expanding its newer businesses.

Pharmaceutical Intermediates Remain the Core Business

Despite the company's expansion plans, pharmaceutical intermediates remain an important part of the business.

The advanced pharmaceutical intermediates segment grew approximately 37.5% year over year to ₹1,174.1 crore in FY26, supported by the company's CDMO activities.

The CDMO opportunity is particularly interesting because long-term customer relationships and validated products can create relatively durable revenue streams.

Acutaas has indicated that its CDMO pipeline could reach approximately ₹1,000 crore by FY28, with several validated products expected to contribute meaningful revenue at peak capacity.

Actual commercialisation and customer adoption will determine how much of this potential becomes revenue.

Battery Chemicals Could Become a Major Growth Engine

Acutaas is also developing its battery-chemicals business.

The company has started commercial supplies of battery chemicals, including electrolyte additives such as VC and FEC. Its first phase of battery-chemical capacity at Jhagadia includes 2,000 MTPA each of VC and FEC, with production covered by long-term contracts according to company-related disclosures.

This gives Acutaas exposure to the growing lithium-ion battery ecosystem.

The opportunity is significant because electrolyte additives are important components in battery manufacturing.

However, investors should distinguish between capacity announcements and actual earnings contribution. The business needs to achieve commercial-scale utilisation and maintain product quality before it can become a major profit contributor.

Semiconductor Materials Add Another Dimension

The semiconductor opportunity is arguably one of the most interesting parts of the company's expansion strategy.

Acutaas' step-down subsidiary Indichem inaugurated a semiconductor materials plant in Gongju, South Korea, in August 2026.

The company has also received approval under the Electronics Component Manufacturing Scheme for its electrolyte-additives project, involving an investment of approximately ₹256.47 crore, with eligible incentives of ₹119.12 crore.

In addition, the board approved up to ₹212 crore of capex for an electronic-grade chemicals plant with 81,000 MT capacity targeted by FY2027-28.

These investments could materially expand the company's addressable market.

But semiconductor chemicals are technically demanding businesses, and commercial success depends on customer qualification, quality standards and execution.

What Could Drive Acutaas Chemicals Share Price?

Pharmaceutical CDMO Growth

The existing pharmaceutical-intermediates business provides the company's current earnings foundation.

A growing CDMO pipeline and successful commercialisation of validated products could support long-term revenue visibility.

Battery Chemicals

Battery materials provide exposure to the global electric-vehicle and energy-storage ecosystem.

Commercial production and long-term contracts could help this segment become a meaningful future contributor.

Semiconductor Materials

The South Korean plant and planned electronic-grade chemical capacity give Acutaas exposure to the semiconductor supply chain.

If customer qualification progresses successfully, this could become a high-value business segment.

Margin Sustainability

FY26 EBITDA margin reached 35.9%, while Q1 FY27 operating margin remained above 30%.

Maintaining healthy margins while scaling new businesses will be critical.

Export Growth

Exports generated approximately ₹1,021.3 crore in FY26, representing a substantial portion of total revenue.

A strong international customer base can support growth but also exposes the company to currency movements and global demand conditions.

Acutaas Chemicals Share Price Target

A precise Acutaas Chemicals share price target should be treated as an estimate rather than a certainty.

The stock closed at approximately ₹3,281.60 on August 28, while the 52-week high was around ₹3,740.

An earlier market estimate from Univest placed a 12-month range around ₹3,732–₹4,212, although that analysis was prepared before the latest financial information and should not be interpreted as a current guaranteed target.

At the current price, investors are already assigning substantial value to the company's growth prospects.

Therefore, further upside would likely require continued earnings growth, successful execution of battery and semiconductor projects and sustained margins.

Is Acutaas Chemicals a Good Stock to Buy?

The company has several strong fundamentals.

FY26 revenue grew 33%, PAT increased 122%, and EBITDA more than doubled. Q1 FY27 also delivered 59% year-on-year revenue growth and more than 70% PAT growth.

The company is also moving into battery and semiconductor materials, potentially creating additional long-term growth engines.

The main concern is expectations.

The stock has already appreciated significantly, and the latest quarter showed a sharp sequential decline in revenue and profit.

That means investors should not rely solely on the headline year-on-year growth numbers.

Acutaas may have a strong business trajectory, but valuation, execution risk and quarterly volatility need to be considered before investing.

How Should Investors Track Acutaas Chemicals Share Price?

Anyone following ACUTAAS share price should monitor both the established pharmaceutical business and the newer growth segments.

Key indicators include revenue growth, EBITDA margins, CDMO order pipeline, battery-chemical capacity utilisation, semiconductor customer qualification, capex, export revenue and cash generation.

The company's recent disclosures include the Q1 FY27 results, investor presentation and announcements concerning semiconductor and battery-chemical expansion.

Investors researching the stock can also use market-analysis resources from Jainam Finance to understand specialty-chemical trends, valuation and broader investment concepts.

Frequently Asked Questions

What is the Acutaas Chemicals share price today?

Acutaas Chemicals closed at approximately ₹3,281.60 on August 28, 2026, according to available market data.

What was Acutaas Chemicals called previously?

Acutaas Chemicals Limited was previously known as Ami Organics Limited.

What is the NSE symbol of Acutaas Chemicals?

The company's NSE symbol is ACUTAAS, while its BSE code is 543349.

What is the 52-week high and low?

The available 52-week range is approximately ₹1,290.05 to ₹3,740.

How were Acutaas Chemicals' latest quarterly results?

For Q1 FY27, total revenue was approximately ₹329.67 crore, up 59.08% year over year, while net profit reached ₹74.99 crore, up 70.4%.

Does Acutaas Chemicals operate in battery chemicals?

Yes. The company has entered battery chemicals, including electrolyte additives such as VC and FEC, with commercial supplies already underway.

Is Acutaas Chemicals entering the semiconductor industry?

Yes. Its step-down subsidiary Indichem has established a semiconductor-materials facility in South Korea, while the company is also investing in electronic-grade chemicals.

What could drive future growth?

Pharmaceutical CDMO expansion, battery chemicals, semiconductor materials, export growth and capacity expansion could become important growth drivers.

Is Acutaas Chemicals suitable for long-term investment?

The company has demonstrated strong earnings growth and is entering potentially attractive specialty-chemical markets. However, the stock has already experienced a substantial re-rating, while new projects carry execution and commercialisation risks. Investors should assess valuation, cash flow, project returns and earnings sustainability before investing.

Final Thoughts

The Acutaas Chemicals share price reflects a specialty-chemicals company that is trying to build several independent growth engines.

The existing pharmaceutical-intermediates business remains important, but battery chemicals and semiconductor materials could significantly change the company's future profile.

Financial performance has been strong. FY26 revenue increased 33% and PAT rose more than 122%, while Q1 FY27 revenue grew 59% year over year.

The caution comes from valuation and execution. Q1 FY27 profit fell sharply sequentially, and the company has several large expansion projects that must eventually generate returns.

For investors researching ACUTAAS, the most important factors are pharmaceutical CDMO growth, battery-chemical capacity, semiconductor-material projects, EBITDA margins, exports, capex, customer contracts, cash flow and valuation. Jainam Finance can provide useful market and investment resources, but investors should conduct independent research before making any investment decision.

Disclaimer: This article is for educational and informational purposes only and should not be considered investment advice. Specialty-chemical stocks can be volatile and are affected by commodity prices, global demand, regulatory requirements, customer concentration and execution risks. Past performance and analyst estimates do not guarantee future returns.